5-amino-salicylate in the management of inflammatory bowel disease

Colorectal Disease

Volumn 3, Issue 4, 2001, Pages 218-222

  Makins, R J ^a   Cowan, R E ^a  

^a O and G   (United Kingdom)

Author keywords

Aminosalicylates; Inflammatory bowel disease

Indexed keywords

BALSALAZIDE; EUDRAGIT; MESALAZINE; OLSALAZINE; PENTOSA; SALAZOSULFAPYRIDINE;

ACUTE DISEASE; BLOOD DYSCRASIA; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; ENTERITIS; HEADACHE; HUMAN; IDIOPATHIC DISEASE; MAINTENANCE THERAPY; NAUSEA; NEPHROTOXICITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; REVIEW; SUPPOSITORY;

EID: 0034882809     PISSN: 14628910     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1318.2001.00265.x     Document Type: Review

References (55)

1. Drug Therapies: Inflammatory bowel disease
2. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (salazopyrine)
3. European Co-operative Crohn's Disease Study (ECCDS): Results of drug treatment
4. Salazopyrine, a new sulphonamide preparation
5. Sulphasalazine: Some Notes on the Discovery and Development of Salazopyrin
6. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis
7. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man
8. Kinetics of 5 aminosalicylic acid after jejunal instillation in man
9. Sulafasalazine intolerance: A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease
10. Immune complex haemolytic anaemia associated with sulfasalazine
11. National cooperative Crohn's disease study: Adverse reactions to study drugs
12. Delayed- release mesalazine (5-aminosalicylic acid): Coat dissolution and excretion in ileostomy subjects
13. Topical and systemic availability of 5-aminosalicylate: Comparisons of three controlled release preparations in man
14. 5-Aminosalicylic acid in a slow-release preparation: Bioavailability, plasma level, and excretion in humans
15. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy
16. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis
17. Double-blind comparison of olsalazine and sulphasalazine in acute ulcerative colitis
18. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid
19. The pharmacology of anti-inflammatory drugs in inflammatory bowel disease
20. Inflammatory intermediaries in inflammatory bowel disease
21. Inflammatory bowel disease
22. The mode of action of the aminosalicylates in inflammatory bowel disease
23. Oxidants and free radicals in inflammatory bowel disease
24. Longterm olsalazine treatment: Pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis
25. Role of intestinal flora in the acetylation of sulphasalzine metabolites
26. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea
27. Pancreatitis induced by 5-aminosalicylic acid
28. Cardiac hypersensitivity to 5-aminosalicylic acid
29. Reversible pulmonary disease and eosinophilia associated with sulphasalazine
30. Nephrotoxicity associated with mesalazine (Asacol). Current problems in pharmacovigilance
31. Antilymphocyte globulin for mesalazine-associated aplastic anaemia
32. Mesalazine-associated thrombocytopenia
33. Alternatives to Sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis
34. Mesalamine capsules for treatment of active ulcerative colitis: Results of a controlled trial
35. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis
36. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis
37. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial
38. Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis
39. Commentary
40. 5-aminosalicylic acid (Pentasa) in enema form for the treatment of active ulcerative colitis
41. Randomised clinical trial of mesalamine (5ASA) enemas in distal ulcerative colitis: A dose-ranging placebo controlled study
42. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
43. Slow-release 5-aminosalicylic acid (Pentasa) for treatment of active Crohn's disease
44. Mesalazine preparations
45. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: Comparison of intraluminal colonic concentrations, serum values, and urinary excretion
46. Sulfasalazine revisited: A meta-analysis of 5 aminosalicylic acid in the treatment of ulcerative colitis
47. 5-Aminosalicylic acid enemas: Effective agent in maintaining remission in leftsided colitis
48. Use of mesalazine slow release suppositories lg three times pre week to maintain remission of ulcerative proctitis: A randomised double blind placebo controlled multicentre study
49. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: A meta-analysis
50. Long-term management of Crohn's disease with mesalamine capsules (Pentasa)
51. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease
52. Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables
53. Mesalazine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease
54. Colorectal cancer prevention in ulcerative colitis: A case-control study
55. Mesalazine-induced apoptosis of colorectal cancer: On the verge of a new chemo preventive era?